On this page
Clotrimazole Topical Solution USP, 1%
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Clotrimazole | 10 mg/mL | 308714 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Azole Antifungal [EPC] | EPC | All 44 members |
| Azoles [CS] | CS | All 44 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 216569-001 | CLOTRIMAZOLE | SOLUTION | CLOTRIMAZOLE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | October 16, 2023 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260430). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Prescription Clotrimazole Topical Solution product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis .
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Gently massage sufficient clotrimazole topical solution USP, 1% into the affected and surrounding skin areas twice a day, in the morning and evening. Clinical improvement, with relief of pruritus, usually occurs within the first week of treatment with clotrimazole topical solution USP, 1%. If the patient shows no clinical improvement after 4 weeks of treatment with clotrimazole topical solution USP, 1%, the diagnosis should be reviewed.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical antifungal agents are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Warnings
openFDA Drug LabelingWARNINGS Clotrimazole Topical Solution is not for ophthalmic use.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following adverse reactions have been reported in connection with the use of clotrimazole: erythema, stinging, blistering, peeling, edema, pruritius, urticaria, burning, and general irritation of the skin. To report SUSPECTED ADVERSE REACTIONS, contact ScieGen Pharmaceuticals, Inc. at 1-855-724-3436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Drug Interactions
openFDA Drug LabelingDrug Interactions Synergism or antagonism between clotrimazole and nystatin, or amphotericin B, or flucytosine against strains of C. albicans has not been reported.
Description
openFDA Drug LabelingDESCRIPTION Clotrimazole Topical Solution USP, 1% contains 10 mg clotrimazole USP, a synthetic antifungal agent having the chemical name 1-(o-Chloro-α,α-diphenylbenzyl) imidazole with the following structural formula: Molecular Formula C 22 H 17 ClN 2 Molecular Weight 344.85 Clotrimazole is an odorless, white crystalline substance. It is practically insoluble in water, sparingly soluble in ether and very soluble in polyethylene glycol 400, ethanol, and chloroform. Each mL of Clotrimazole Topical Solution, USP 1% contains 10 mg clotrimazole USP in a nonaqueous vehicle of polyethylene glycol 400. Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Acute overdosage with topical application of clotrimazole is unlikely and would not be expected to lead to a life-threatening situation.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Clotrimazole Topical Solution, USP 1% is supplied as follows: NDC 50228-502-08 in one 10 mL round bottle in a carton NDC 50228-502-30 in one 30 mL round bottle in a carton NDC 50228-502-31 in one 30 mL oval bottle in a carton Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CLOTRIMAZOLE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 71399-0666-3 | 71399-0666 | Akron Pharma Inc. | 1 BOTTLE in 1 CARTON (71399-0666-3) / 30 mL in 1 BOTTLE | May 4, 2024 |
| 71399-0666-6 | 71399-0666 | Akron Pharma Inc. | 2 BOTTLE in 1 CARTON (71399-0666-6) / 30 mL in 1 BOTTLE | March 25, 2024 |
| 71297-030-02 | 71297-030 | Allegis Holdings, LLC | 2 BOTTLE in 1 CARTON (71297-030-02) / 10 mL in 1 BOTTLE | November 12, 2025 |
| 72162-2178-3 | 72162-2178 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (72162-2178-3) / 30 mL in 1 BOTTLE | July 25, 2019 |
| 50228-502-08 | 50228-502 | ScieGen Pharmaceuticals, Inc | 1 BOTTLE in 1 CARTON (50228-502-08) / 10 mL in 1 BOTTLE | October 16, 2023 |
| 50228-502-30 | 50228-502 | ScieGen Pharmaceuticals, Inc | 1 BOTTLE in 1 CARTON (50228-502-30) / 30 mL in 1 BOTTLE | October 16, 2023 |
| 50228-502-31 | 50228-502 | ScieGen Pharmaceuticals, Inc | 1 BOTTLE in 1 CARTON (50228-502-31) / 30 mL in 1 BOTTLE | October 16, 2023 |
| 52817-800-30 | 52817-800 | TruPharma LLC | 1 BOTTLE in 1 CARTON (52817-800-30) / 30 mL in 1 BOTTLE | July 25, 2019 |
| 71399-0666 | 71399-0666 | Akron Pharma Inc. | — | October 16, 2023 |
| 71297-030 | 71297-030 | Allegis Holdings, LLC | — | November 12, 2025 |
| 72162-2178 | 72162-2178 | Bryant Ranch Prepack | — | July 25, 2019 |
| 50228-502 | 50228-502 | ScieGen Pharmaceuticals, Inc | — | October 16, 2023 |
| 52817-800 | 52817-800 | TruPharma LLC | — | July 25, 2019 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.